- Home
- MHD vs PHAR Comparison
MHD vs PHAR Comparison
Compare MHD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHD
- PHAR
- Stock Information
- Founded
- MHD N/A
- PHAR 1988
- Country
- MHD United States
- PHAR Netherlands
- Employees
- MHD N/A
- PHAR N/A
- Industry
- MHD Investment Bankers/Brokers/Service
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MHD Finance
- PHAR Health Care
- Exchange
- MHD Nasdaq
- PHAR Nasdaq
- Market Cap
- MHD 592.9M
- PHAR 718.1M
- IPO Year
- MHD N/A
- PHAR N/A
- Fundamental
- Price
- MHD $11.16
- PHAR $11.00
- Analyst Decision
- MHD
- PHAR Strong Buy
- Analyst Count
- MHD 0
- PHAR 3
- Target Price
- MHD N/A
- PHAR $30.00
- AVG Volume (30 Days)
- MHD 124.9K
- PHAR 3.0K
- Earning Date
- MHD 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- MHD 4.16%
- PHAR N/A
- EPS Growth
- MHD N/A
- PHAR N/A
- EPS
- MHD N/A
- PHAR N/A
- Revenue
- MHD N/A
- PHAR $320,708,000.00
- Revenue This Year
- MHD N/A
- PHAR $13.31
- Revenue Next Year
- MHD N/A
- PHAR $7.68
- P/E Ratio
- MHD N/A
- PHAR N/A
- Revenue Growth
- MHD N/A
- PHAR 24.13
- 52 Week Low
- MHD $9.92
- PHAR $6.65
- 52 Week High
- MHD $12.18
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- MHD 47.85
- PHAR 51.11
- Support Level
- MHD $11.06
- PHAR $10.23
- Resistance Level
- MHD $11.17
- PHAR $11.21
- Average True Range (ATR)
- MHD 0.08
- PHAR 0.27
- MACD
- MHD 0.00
- PHAR -0.14
- Stochastic Oscillator
- MHD 45.26
- PHAR 34.01
About MHD Blackrock MuniHoldings Fund Inc.
Blackrock Muniholdings Fund Inc is a closed-end management investment company. The fund's objective is to provide shareholders with current income exempt from U.S. federal income taxes. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.